| 179.95 0 (0%) | 06-12 09:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 210.22 | 1-year : | 245.54 |
| Resists | First : | 179.99 | Second : | 210.22 |
| Pivot price | 179.11  |
|||
| Supports | First : | 178.92 | Second : | 178.25 |
| MAs | MA(5) : | 179.94 |
MA(20) : | 179.01 |
| MA(100) : | 170.49 |
MA(250) : | 156.8 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 97.6 | D(3) : | 97.6 |
| RSI | RSI(14): 74.8 | |||
| 52-week | High : | 179.99 | Low : | 125.94 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MASI ] has closed below upper band by 15.3%. Bollinger Bands are 81.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 67 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 180.21 - 181.12 | 181.12 - 181.87 |
| Low: | 177.81 - 178.79 | 178.79 - 179.6 |
| Close: | 178.52 - 180.05 | 180.05 - 181.31 |
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Iris, iSirona, Replica, and UniView; and brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
Sun, 16 Aug 2026
Masimo Shareholder Action Reminder - TMX Newsfile
Fri, 12 Jun 2026
Danaher Closes Masimo Deal Shifting Monitoring Story Inside Diagnostics Platform - simplywall.st
Wed, 10 Jun 2026
Masimo Received Notice of Delisting - TradingView
Wed, 10 Jun 2026
Danaher completes acquisition of Masimo, company delists from Nasdaq - Investing.com
Mon, 08 Jun 2026
Danaher (DHR) Moves Towards Acquisition of Masimo (MASI) - GuruFocus
Mon, 18 May 2026
Masimo Corporation (MASI) Stock Analysis: A Look At Revenue Growth And Robust Returns - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 52 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 6.2 (%) |
| Held by Institutions | 104.7 (%) |
| Shares Short | 3,500 (K) |
| Shares Short P.Month | 3,880 (K) |
| EPS | 4.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.06 |
| Profit Margin | 4.9 % |
| Operating Margin | 23.6 % |
| Return on Assets (ttm) | 10.1 % |
| Return on Equity (ttm) | 24.9 % |
| Qtrly Rev. Growth | 8.5 % |
| Gross Profit (p.s.) | 18.34 |
| Sales Per Share | 29.78 |
| EBITDA (p.s.) | 7.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 232 (M) |
| Levered Free Cash Flow | 328 (M) |
| PE Ratio | 44.43 |
| PEG Ratio | 4.8 |
| Price to Book value | 11.94 |
| Price to Sales | 6.04 |
| Price to Cash Flow | 40.62 |
| Dividend | 1 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|